Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort

JAMA

Volumn 280, Issue 1, 1998, Pages 55-60

  Mandelbrot, Laurent ^a   Le Chenadec, Jérôme ^b   Berrebi, Alain ^c   Bongain, André ^d   Bénifla, Jean Louis ^e   Delfraissy, Jean François ^f   Blanche, Stéphane ^g   Mayaux, Marie Jeanne ^b  

^a Inst Natl S et de la Rech Med ^*  (France)

^b INSERM   (France)

^c Serv Univ Psychiat l'Enfant l'A   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e BICHAT HOSPITAL   (France)

^f Hop de Kremlin Bicêtre   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; AMNION FLUID ANALYSIS; ARTICLE; CHEMOPROPHYLAXIS; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; VAGINAL DELIVERY; VIRUS TRANSMISSION;

EID: 0032123511     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.1.55     Document Type: Article

References (40)

1. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model: the HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol. 1995;142:1330-1337.
2. Brossard Y, Aubin JT, Mandelbrot L, et al. Frequency of early in utero HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. AIDS. 1995;9:359-366.
3. Bryson YY, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med. 1992; 327:1246-1247.
4. Mandelbrot L. Timing of in utero HIV infection: implications for prenatal diagnosis and management of pregnancy. AIDS Patient Care STD. 1997;11:139-148.
5. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts: SEROGEST and the French Pediatric HIV Infection Study Group. Am J Obstet Gynecol. 1996;175:661-667.
6. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;334:1617-1623.
7. St Louis ME, Kamenga M, Brown C, Fransen K, Coppens M, Piot P. Risk for perinatal HIV-1 transmission according to maternal, immunologic, virologic, and placental factors. JAMA. 1993;269:2853-2859.
8. Temmerman M, Nyong'o AO, Bwayo J, et al. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol. 1995;172:700-705.
9. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: maternal immune status and obstetric factors: the European Collaborative Study. AIDS. 1996;10:1675-1681.
10. Dunn DT, Newell ML, Mayaux MJ, et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies: Perinatal AIDS Collaborative Transmission Studies. J Acquir Immune Defic Syndr. 1994;7:1064-1066.
11. The European Collaborative Study. Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet. 1994;343:1464-1467.
12. Kind C. Mother-to-child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery: Paediatric AIDS Group of Switzerland. Eur J Pediatr. 1995;154:542-545.
13. Kuhn L, Stein ZA, Thomas PA, et al. Maternal-infant HIV transmission and circumstances of delivery. Am J Public Health. 1994;84:1110-1115.
14. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV: Perinatal AIDS Collaborative Transmission Studies. AIDS. 1998;12: 301-308.
15. Thomas PA, Weedon J, Krasinski K, et al. Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatr Infect Dis J. 1994; 13:489-494.
16. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr. 1993; 6:298-302.
17. Boyer RJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA. 1994;271:1925-1930.
18. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331: 1173-1180.
19. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996;275:1483-1488.
20. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. J Pediatr. 1997;131:857-862.
21. Blanche S, Rouzioux C, Moscato ML, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1: HIV Infection in Newborns French Collaborative Study Group. N Engl J Med. 1989;320:1643-1648.
22. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal viral load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies: SEROGEST Cohort Group. J Infect Dis. 1997;175:172-175.
23. Early diagnosis of HIV infection in infants: report of a consensus workshop, Siena, Italy, January 17-28, 1992. J Acquir Immune Defic Syndr. 1992;5: 1169-1178.
24. Mayaux MJ, Blanche S, Rouzioux C, et al. Maternal factors associated with perinatal HIV-1 transmission: the French cohort study: 7 years of follow-up observation: the French Pediatric HIV Infection Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:188-194.
25. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service task force on the use of zidovudine to decrease perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Weekly Rep. 1994;43: 1-20.
26. Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS. 1997;11:429-435.
27. Newell ML, Parazzini F, Mandelbrot L, et al. A randomised trial of mode of delivery in women infected with the human immunodeficiency virus. Br J Obstet Gynaecol. 1998;105:281-285.
28. Biggar RJ, Mtimavalye L, Justesen A, et al. Does umbilical cord blood polymerase chain reaction positivity indicate in utero (pre-labor) HIV infection? AIDS. 1997;11:1375-1382.
29. Romero R, Mazor M. Infection and preterm labor. Clin Obstet Gynecol. 1988;31:553-561.
30. Scaravelli G, Thorne C, Newell ML. The management of pregnancy and delivery in HIV-infected women in Europe. Eur J Obstet Gynecol. 1995;62: 7-13.
31. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS. 1998;12:205-210.
32. Loussert-Ajaka I, Mandelbrot L, Delmas MC, et al. HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS. 1997;11:1575-1581.
33. Sperling R, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996; 335:1621-1629.
34. Lin HH, Kao JH, Hsu HY, Mizokami M, Hirano K, Chen DS. Least microtransfusion from mother to fetus in elective cesarean delivery. Obstet Gynecol. 1996;87:244-248.
35. Van de Perre P. Postnatal transmission of human immunodeficiency virus type 1: the breast-feeding dilemma. Am J Obstet Gynecol 1995;173: 483-487.
36. Mandelbrot L, Burgard M, Teglas JP, et al. Détection fréquente du VIH dans le produit d'aspiration pharyngée et gastrique de nouveauxnés de mères infectées par le VIH-1 [abstract]. In: Premier Séminaire Annuel de Recherche Clinique sur l'Infection par le VIH 1987. Paris, France: Agence Nationale de Recherches Sur le SIDA;1997: A42.
37. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997;176:478-489.
38. Högberg U, Innala E, Sandström A. Maternal mortality in Sweden, 1980-1988. Obstet Gynecol. 1994;84:240-244.
39. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS. 1995;9:913-917.
40. Bulterys M, Chao A, Dushimimana A, Saah A. Fatal complications after cesarean section in HIV-infected women. AIDS. 1996;10:923-924.